3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Myasthenia Gravis
2
Interventions
Specimen Handling
602
pembrolizumab
557
Magnetic Resonance Spectroscopy
527
Carboplatin
422
Cyclophosphamide
370
Cisplatin
369
Biopsy
349
Paclitaxel
304
Gemcitabine
299
Nivolumab
298
Radiotherapy
256
Bevacizumab
232
Dexamethasone
207
fludarabine
203
Docetaxel
185
durvalumab
177
atezolizumab
172
Oxaliplatin
170
Fluorouracil
166
venetoclax
164
Rituximab
163
Pemetrexed
161
Doxorubicin
157
Radiation
155
Capecitabine
155
Radiosurgery
145
Etoposide
137
Leucovorin
133
Ipilimumab
132
Lenalidomide
129
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
inebilizumab
×
90 days
×
Clear all
NCT06987539
2026-05-29
THYME
Amgen
Phase 2
Recruiting
15 enrolled
NCT04524273
2026-05-15
MINT
Amgen
Phase 3
Active not recruiting
238 enrolled
36 charts